High quality clinical data is needed in your study analysis to avoid difficulties and delays as you seek approval with your regulatory submission. Do not let poor quality data slow down the pace of your trial.
This is more critical as the pharmaceutical industry unites to defeat the COVID-19 global pandemic. Governments want to bring any vaccine or effective treatments to market as quickly as possible, and high quality clinical data will bring efficiencies to trials and faster regulatory submissions to support that aim.
We offer expertise via statistical support in designing COVID-19 trials and in collecting, analysing and reporting trial data.
Quanticate's experience in respiratory trial data has seen countless regulatory approvals.
We have undertaken vaccine and antiviral trials and have proven to experience in this therapeutic area.